|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Mr. Albert G. White III||Pres, CEO & Non-Independent Director||1,81M||N/D||1970|
|Mr. Brian G. Andrews||Exec. VP, CFO & Treasurer||762,01k||N/D||1979|
|Mr. Daniel G. McBride||Exec. VP & COO||1,14M||N/D||1964|
|Ms. Holly R. Sheffield||Pres of CooperSurgical, Inc.||815,4k||N/D||1971|
|Mr. Agostino Ricupati||Sr. VP of Fin. & Tax and Chief Accounting Officer||N/D||N/D||1967|
|Mr. Kim Duncan||VP of Investor Relations & Risk Management||N/D||N/D||N/D|
|Mr. Mark J. Drury||VP, Gen. Counsel & Corp. Sec.||N/D||N/D||1976|
|Mr. Juan Carlos AragÃ³n||Pres of CooperVision Specialty EyeCare Division||N/D||N/D||N/D|
The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
L'ISS Governance QualityScore di The Cooper Companies, Inc. al 1 luglio 2021 è 4. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 2; retribuzione: 7.